Wedbush Downgrades AngioDynamics (ANGO) to Underperform; CEO Out, Q4 Results Fall Short, Slashing our 2012 Outlook
Tweet
Share
E-mailGet Alerts ANGO Hot Sheet
Price: $15.85 +1.21%
Rating Summary:
8 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush downgraded AngioDynamics (NASDAQ: ANGO) from Neutral to Underperform. PT cut by $2 to $12.
Wedbush analyst said, "It is a very tough operating environment, and the outlook for ANGO’s performance has recently gotten a lot cloudier. With a management transition now underway, accelerated deterioration of the core business, the likelihood of a negative top-line comparison next year due to the loss of the LC Bead distribution agreement, and a lack of visibility on the timing of NanoKnife clinical milestones, we think ANGO will be “dead money” for at least the next year."
"We have cut our sales forecast by $14.9 million to $211.2 million. This would represent a decline of approximately 2.2% from the expected FY 2011 level. Our EPS estimate for FY 2012 comes down by $0.07 to $0.48, which would represent a sixth consecutive year of essentially flat EPS performance."
For more ratings news on AngioDynamics click here and for the rating history of AngioDynamics click here.
Shares of AngioDynamics closed at $14.57 yesterday.
Wedbush analyst said, "It is a very tough operating environment, and the outlook for ANGO’s performance has recently gotten a lot cloudier. With a management transition now underway, accelerated deterioration of the core business, the likelihood of a negative top-line comparison next year due to the loss of the LC Bead distribution agreement, and a lack of visibility on the timing of NanoKnife clinical milestones, we think ANGO will be “dead money” for at least the next year."
"We have cut our sales forecast by $14.9 million to $211.2 million. This would represent a decline of approximately 2.2% from the expected FY 2011 level. Our EPS estimate for FY 2012 comes down by $0.07 to $0.48, which would represent a sixth consecutive year of essentially flat EPS performance."
For more ratings news on AngioDynamics click here and for the rating history of AngioDynamics click here.
Shares of AngioDynamics closed at $14.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Berenberg Downgrades Inter Parfums (IPAR) to Hold
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
